4D Molecular Therapeutics, Inc. FDMT · Stock Open 4D Molecular Therapeutics, Inc. in new tab
4D Molecular Therapeutics, Inc. Analysis (FDMT)
Is 4D Molecular Therapeutics, Inc. a good investment? 4D Molecular Therapeutics, Inc. (FDMT) is currently trading at 15.24 USD. Market analysts have a consensus price target of 27.82 USD. This suggests a potential upside from current levels.
Earnings Schedule: 4D Molecular Therapeutics, Inc. is expected to release its next earnings report on Nov. 10, 2026. The market consensus estimate for Forward EPS is -4.09.
Investor FAQ
Does 4D Molecular Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is 4D Molecular Therapeutics, Inc.?
4D Molecular Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 10, 2026. The company currently has a trailing EPS of -2.65.
Company Profile
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Community Discussion